The previous studies showed that FBXW7 is an anticancer gene (Fiore et al., 2019; Imura et al., 2014; Li et al., 2019; Xiao et al., 2018; Zhao et al., 2017), and then, FBXW7 suppresses inflammatory signaling via decreasing C/EBPδ and its target gene TLR4 in macrophages and tumor cells (Balamurugan et al., 2013), and FBXW7 also inhibits hepatic inflammation in nonalcoholic fatty liver disease (C. Zhang et al., 2019). The gene discussed is CEBPD; the disease is metabolic dysfunction-associated steatotic liver disease.